SG11201901374WA - Antibiotic compounds - Google Patents

Antibiotic compounds

Info

Publication number
SG11201901374WA
SG11201901374WA SG11201901374WA SG11201901374WA SG11201901374WA SG 11201901374W A SG11201901374W A SG 11201901374WA SG 11201901374W A SG11201901374W A SG 11201901374WA SG 11201901374W A SG11201901374W A SG 11201901374WA SG 11201901374W A SG11201901374W A SG 11201901374WA
Authority
SG
Singapore
Prior art keywords
international
compounds
merrifield
lane
centre
Prior art date
Application number
SG11201901374WA
Other languages
English (en)
Inventor
Dr Paul Meo
Dr Nawaz Khan
Original Assignee
Discuva Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Discuva Ltd filed Critical Discuva Ltd
Publication of SG11201901374WA publication Critical patent/SG11201901374WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201901374WA 2016-08-22 2017-08-22 Antibiotic compounds SG11201901374WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1614314.1A GB201614314D0 (en) 2016-08-22 2016-08-22 Antibiotic compounds
PCT/GB2017/052478 WO2018037223A1 (en) 2016-08-22 2017-08-22 Antibiotic compounds

Publications (1)

Publication Number Publication Date
SG11201901374WA true SG11201901374WA (en) 2019-03-28

Family

ID=57045563

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201901374WA SG11201901374WA (en) 2016-08-22 2017-08-22 Antibiotic compounds

Country Status (15)

Country Link
US (1) US20190194179A1 (cg-RX-API-DMAC7.html)
EP (1) EP3500567A1 (cg-RX-API-DMAC7.html)
JP (1) JP2019528291A (cg-RX-API-DMAC7.html)
KR (1) KR20190046894A (cg-RX-API-DMAC7.html)
CN (1) CN109923111A (cg-RX-API-DMAC7.html)
AU (1) AU2017316742A1 (cg-RX-API-DMAC7.html)
BR (1) BR112019003427A2 (cg-RX-API-DMAC7.html)
CA (1) CA3034000A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019002624A2 (cg-RX-API-DMAC7.html)
EA (1) EA201990551A1 (cg-RX-API-DMAC7.html)
GB (1) GB201614314D0 (cg-RX-API-DMAC7.html)
MX (1) MX2019001978A (cg-RX-API-DMAC7.html)
PH (1) PH12019500360A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201901374WA (cg-RX-API-DMAC7.html)
WO (1) WO2018037223A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3636645A1 (de) 2018-10-11 2020-04-15 Bayer Aktiengesellschaft Verfahren zur herstellung schwefel-substituierter pyridinderivate
KR102793543B1 (ko) 2018-10-11 2025-04-11 바이엘 악티엔게젤샤프트 이미다졸 유도체의 제조 방법
TWI841671B (zh) 2019-01-24 2024-05-11 日商第一三共股份有限公司 具有取代基之脲化合物
US20220125763A1 (en) 2019-02-22 2022-04-28 Anifera Limited Compositions providing enhanced antibacterial activity against gram-positive bacteria and use thereof
CN111808093B (zh) * 2019-04-12 2023-05-16 中国医学科学院医药生物技术研究所 一种新德里金属-β-内酰胺酶-1抑制剂
BR112021020055A2 (pt) * 2019-04-12 2021-12-07 Mitobridge Inc Indutores de hmox1
US12528798B2 (en) 2019-10-29 2026-01-20 Lg Chem, Ltd. Compound for crop protectant
CN116528873B (zh) * 2020-11-19 2025-08-22 A&J科学有限公司 新型化合物、其制造方法及包含其的抗生素组合物
CN113185475A (zh) * 2021-04-29 2021-07-30 江苏永凯化学有限公司 一种高效低污染的精恶唑禾草灵生产工艺
KR20240016304A (ko) * 2021-05-31 2024-02-06 장슈 야홍 메디텍 코퍼레이션 리미티드 7-니트로-8-하이드록시퀴놀린 유도체, 이의 제조 방법 및 이의 의학적 용도
KR102754999B1 (ko) * 2022-01-06 2025-01-21 충남대학교산학협력단 신규한 화합물 및 이를 포함하는 결핵균 또는 비결핵항산균 감염질환 치료용 약제학적 조성물
JP2025522339A (ja) * 2022-06-01 2025-07-15 クダ セラピューティクス インコーポレイテッド イミダゾピリジン及びオキサゾロピリジン誘導体及びその類似体、その調製方法、HIF-1/2a経路阻害の方法、並びに、フェロトーシスの誘導
JP2026505647A (ja) * 2022-12-16 2026-02-17 インベンション・セラピューティクス・インコーポレイテッド ベンゾイミダゾール誘導体
KR102840252B1 (ko) * 2023-04-27 2025-07-30 한국화학연구원 시아노벤즈이미다졸 유도체, 약제학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물
CN117003710A (zh) * 2023-07-19 2023-11-07 镇江先锋植保科技有限公司 一种2-巯基-6-氯苯并恶唑的制备方法
AU2024331213A1 (en) * 2023-09-01 2026-04-16 Immvention Therapeutix, Inc. Substituted benzoxazolylamino benzoxazoles

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8604217B2 (en) * 2009-11-12 2013-12-10 Selvita S.A. Compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent
JP5786402B2 (ja) * 2011-03-29 2015-09-30 コニカミノルタ株式会社 光学フィルム、及びそれを用いた偏光板、液晶表示装置
WO2016039939A1 (en) * 2014-09-09 2016-03-17 Ptc Therapeutics, Inc. Bicyclic and tricyclic substituted 2-pyridinone antibacterial compounds

Also Published As

Publication number Publication date
EP3500567A1 (en) 2019-06-26
PH12019500360A1 (en) 2019-11-11
US20190194179A1 (en) 2019-06-27
GB201614314D0 (en) 2016-10-05
KR20190046894A (ko) 2019-05-07
AU2017316742A1 (en) 2019-04-11
BR112019003427A2 (pt) 2019-05-21
CO2019002624A2 (es) 2019-05-31
CA3034000A1 (en) 2018-03-01
EA201990551A1 (ru) 2019-12-30
MX2019001978A (es) 2019-08-01
JP2019528291A (ja) 2019-10-10
CN109923111A (zh) 2019-06-21
WO2018037223A1 (en) 2018-03-01

Similar Documents

Publication Publication Date Title
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201908813QA (en) Anti-sirp alpha antibodies
SG11201805940QA (en) Benzopyrazole compounds and analogues thereof
SG11202000266VA (en) Quinoline derivatives for treating infections with helminths
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201909960UA (en) Methods for improving memory and cognition and for treating memory and cognitive disorders
SG11201811432WA (en) Rna for cancer therapy
SG11201807437XA (en) Antibodies specific to human poliovirus receptor (pvr)
SG11201908919XA (en) Combination therapies targeting pd-1, tim-3, and lag-3
SG11201809470RA (en) Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseases in animals
SG11201811442UA (en) Formulation of a peptide vaccine
SG11201909841RA (en) Antitumoral compounds
SG11201809908TA (en) Stabilized glycopeptide antibiotic formulations
SG11201806868TA (en) Compositions and methods for protecting against airborne pathogens and irritants
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201810965YA (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
SG11201809537VA (en) Urea motif containing compounds and derivatives thereof as antibacterial drugs
SG11201803918VA (en) Production of steviol glycosides in recombinant hosts
SG11201811345TA (en) Combination of ceftibuten and clavulanic acid for use in the treatment of bacterial infections
SG11201809875VA (en) Compositions and methods for treating spinal muscular atrophy
SG11201805001UA (en) Method of treating influenza a
SG11201805649UA (en) Therapeutic anti-cd9 antibody
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same
SG11201803643TA (en) Virulence attenuated bacteria for treatment of malignant solid tumors
SG11201807963WA (en) Compositions useful in the prevention and/or treatment of disorders of the oral cavity, upper airways and esophagus